<DOC>
	<DOCNO>NCT01471171</DOCNO>
	<brief_summary>The aim present study evaluate effect aclidinium bromide 400 μg twice day ( BID ) administer twice day versus placebo exercise endurance hyperinflation dyspnoea rest exercise 3 week treatment .</brief_summary>
	<brief_title>Efficacy Safety Aclidinium Bromide 400 µg BID ( Twice Day ) Compared Placebo Patients With Stable Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male female patient age ≥ 40 stable moderate severe COPD ( Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ) . Postsalbutamol Forced Expiratory Volume one second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value Postsalbutamol FEV1/Forced Vital Capacity ( FVC ) &lt; 70 % . Current exsmokers ≥ 10 packyears Functional residual capacity ( FRC ) measure body plethysmography Screening Visit ≥ 120 % predict value History current diagnosis asthma Signs exacerbation within 6 week ( 3 month result hospitalisation ) prior screen visit runin period . Clinically significant respiratory and/or cardiovascular condition laboratory abnormality . Conditions use anticholinergic drug contraindicate , know symptomatic prostatic hypertrophy , bladder neck obstruction narrowangle glaucoma . Patients oxygen saturation &lt; 85 % cycle exercise room air Screening Visit , Run Visit Visit 1 . Contraindications cardiopulmonary exercise test . Patient investigator 's opinion need start pulmonary rehabilitation program study and/or patient started/finished pulmonary rehabilitation least 3 month prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Antimuscarinic</keyword>
</DOC>